Key takeaways
- Across rolling one-year periods from 1976 to 2022, investing a lump sum beat 12-month cost averaging between 61.6% and 73.7% of the time, depending on the market tested.
- The median advantage was 2.2 percentage points for a 100% equity portfolio, 1.8 points for a 60/40 and 1.2 points for a 40/60 split.
- Cost averaging wins when markets fall over the phase-in window. That is roughly 3 periods in 10, and it is the same 3 in 10 that make people want it.
- Constantinides showed in 1979 that the rigidity of a fixed schedule makes it inferior on an a priori basis, before any historical data is consulted.
- The gap is a cost of insurance, not a mistake. Whether 1.8 points is worth paying depends on what you'd do after a 20% fall on day two.
Say two sisters inherit the same £120,000 on the same afternoon. One moves the lot into her portfolio that week and goes back to her life. The other sets up an instruction for £10,000 a month over the next year, so she can't possibly put everything in at the top.
Which one would you rather be?
Most people pick the second, and they pick her quickly. The drip feels like the adult choice — patient, modest about your own judgement, safe from the worst possible day. You've probably been offered it as the responsible default, whether the money came from selling a property, a bonus or an inheritance you didn't plan for. The evidence says it costs you money most of the time, and the reason is duller than the argument for it.
What the lump sum vs cost averaging data actually says
Vanguard tested the question across three markets over rolling one-year periods from 1976 to 2022. It compared investing everything at once against splitting the same sum across a phase-in schedule. Investing at once won between 61.6% and 73.7% of the time, depending on which market you look at.
The markets tested were the Russell 3000 for the US from 1979, the FTSE All-Share for the UK from 1986, and the S&P/ASX 300 for Australia from 1992. The multi-asset work used the MSCI World Index alongside the Bloomberg U.S. Aggregate Bond Index across the full 1976 to 2022 window.
The size of the gap matters more than the win rate. Measured over a one-year rolling period against three-month averaging splits, here's what the wait cost.
| Portfolio | Median advantage to investing at once |
|---|---|
| 100% equities | 2.2 percentage points |
| 60/40 equity-bond | 1.8 points |
| 40/60 equity-bond | 1.2 points |
Look at the direction of that pattern before anything else. The more equity you hold, the more the delay costs you. That's the whole mechanism in one line, and it isn't about timing at all.
Why it happens, and it isn't clever
Markets go up more often than they go down. That's it. If an asset has a positive expected return, then any period you spend out of it is a period you're not earning that return. Cost averaging is a schedule that guarantees you'll be partly out of the market for the whole phase-in window, by construction.
Over a twelve-month drip, your average exposure is roughly half your target. You're holding a portfolio that is half cash for a year, then switching. So here's the awkward question: if you wouldn't choose a half-cash portfolio as your long-run allocation, why is it the right one for the twelve months you happen to be starting in?
This isn't a new observation. George Constantinides challenged the idea that averaging in reduces risk in the Journal of Financial and Quantitative Analysis in 1979, arguing the approach is suboptimal against alternative strategies. Knight and Mandell went further in Financial Services Review in 1992, testing it three ways — graphical analysis, historical stock market returns and Monte Carlo simulation — and finding that optimal rebalancing and buy-and-hold beat averaging in all three.
Neither paper needed a bull market to make the argument. The result falls out of the assumption that expected returns are positive, which is the same assumption you're making by investing at all.
So why does anyone drip?
Here's the part the win-rate statistic hides. Investing at once loses roughly three times in ten. Those aren't random losses scattered evenly — they cluster in exactly the periods where markets fall over the phase-in window, which is to say the periods you are most frightened of.
So imagine you're the sister who went in at once, and the market drops 25% over the following six months. The arithmetic says hold. The question is whether you will. Sell at the bottom and you convert a temporary paper loss into a permanent one, and the cost of that dwarfs 1.8 percentage points. We've looked at the size of that behavioural cost separately in the work on what bad timing does to investor returns, and the gap there runs at over a percentage point a year on the average dollar.
Read that way, cost averaging isn't a return strategy at all. It's insurance against your own reaction, and the median 1.8 points is the premium. Insurance that costs something and pays out in the bad state is a perfectly rational purchase. It just shouldn't be sold as the higher-returning option, because it isn't.
There's a second, narrower case. Say the sum is genuinely large relative to the portfolio you already hold — a windfall that doubles your invested assets overnight. Then the sequence of returns in the first year carries unusual weight. That's the same mechanism that makes the years around retirement dominate outcomes, which we covered in the piece on how return order changes results on identical returns. Phasing in reduces the variance of that first-year outcome. It doesn't improve the expected one.
Where dollar cost averaging genuinely earns its keep
Cost averaging's best historical showing comes from extended declines rather than sharp ones. A drip schedule through a market that grinds lower for years buys progressively more units, and the strategy's relative performance improves the longer the fall lasts. Japan through the 1990s is the case usually cited.
The catch is that you can't identify that regime in advance. If you could, the correct response wouldn't be a twelve-month drip — it would be not buying yet. A schedule chosen because you fear a decline is a weak version of a market call, and it commits you to buying through the decline anyway.
One distinction that gets lost: your regular monthly investing out of a salary isn't cost averaging in this sense. That's just money going in as it arrives, and there's no lump sum sitting in cash for it to lose against. The comparison only bites when you already hold the full amount.
What choosing cost averaging over a lump sum costs in practice
On £100,000, a median 1.8-point shortfall over the phase-in year is about £1,800 of forgone return in the middle case. That is real, but it isn't catastrophic, and it's roughly what a year of a 1% fund fee costs you on a similar balance — a comparison we ran in detail in the work on what fees compound to over thirty years.
The asymmetry is worth stating plainly. The cost of phasing in is bounded and you know it in advance. The cost of investing at once and then panicking is unbounded, and you only find out afterwards. People who know they're prone to the second problem are not being irrational when they pay to avoid it.
A worked example you can follow
Go back to the sister with the schedule, and put yourself in her shoes. Her £120,000 goes in at £10,000 a month. In month one she holds £10,000 invested and £110,000 in cash. By month six she's at £60,000 and £60,000. Averaged across the year, a little over half the money is invested.
So for twelve months she's running an allocation she never chose. If her target is 60/40, the drip has her at roughly 30/70 for the first half of the year, drifting up to target by December. Nobody would write that down as a plan. It's a by-product of the schedule.
Apply the median 1.8-point figure for a 60/40 and the shortfall is around £2,160 over the year. Does that number frighten you? That's the whole question, and only you can answer it. It's a rounding error against a thirty-year horizon, and it's a fortnight's income for a lot of people.
The comparison also assumes she actually finishes. In practice a drip that starts into a falling market often stops — the schedule that was meant to remove the decision hands you twelve fresh chances to make it. That failure mode doesn't show up in any backtest, because backtests always complete the schedule.
The objections worth taking seriously
Critics of the lump-sum result make three arguments, and they're not equally strong.
The first is that the studies measure the wrong thing. They compare expected wealth, when what you actually live through is the path. That objection is fair as far as it goes. Phasing in genuinely does cut the dispersion of first-year outcomes, and if early losses hurt you more than early gains please you, the schedule can be the better fit even at a lower expected return.
The second is that the win rate is period-dependent — that four decades ending in 2022 flatter equities because the sample sits inside a long disinflation. This is the strongest version, and it's partly right. The honest answer is that the result also holds in the analytical papers, which don't depend on any sample at all, and that it held across three markets with different starting points and different crises.
The third argument is that phasing in lets you buy lower if the market falls. That one doesn't survive contact with the arithmetic. It's a claim about direction, and if you had a view on direction you'd act on it directly rather than through a schedule that also buys on the way up.
What would change the conclusion
Three things would move this, and one of them is measurable today.
First, if expected returns were negative, the ordering reverses immediately. Nobody holds that view about a diversified global portfolio over a multi-decade horizon, but it's the assumption doing all the work, and it's worth being honest that it's an assumption.
Second, the win rate isn’t constant across valuation levels. Work in the Journal of Financial Planning has tested whether the CAPE ratio flags periods when averaging does better, and reports that investing at once still wins at extreme valuations, just less often than its overall average. That’s a shift in odds, not a reversal, and it isn’t a licence to time.
Third, cash rates matter. Every one of these comparisons assumes your un-invested money earns a cash return. When cash yields 5%, the drag from sitting out is smaller than when it yields nothing, and the gap narrows. It doesn't close, because equity risk premia have historically exceeded cash by more than that, but the premium you're paying for the insurance falls. The same trade-off decides whether an invested emergency fund is worth the drawdown risk it takes on.
Picture the same drip in two rate environments. If your un-invested balance earns 4% and the portfolio's expected return is 7%, the opportunity cost of sitting half out for a year is roughly 1.5 points, not 7. When cash paid nothing, the same delay cost you the full spread. The strategy's price tag moves with the deposit rate, which is a reason to check the arithmetic rather than inherit a rule of thumb from a different rate environment.
How to think about lump sum vs cost averaging
The evidence supports investing at once as the higher-expected-return choice, by a margin that's real but modest, and it has been stable across three markets and four decades. If you're confident you'll sit through a bad first year, that's the option the data points to.
If you're not confident, the honest framing isn't that cost averaging is safer. It's that you're buying a known, bounded cost to reduce the chance of an unknown, unbounded one. So which sister are you — and, more usefully, which one are you on the morning the market opens sharply lower? Price the premium, decide whether you want it, and don't pretend the trade is free.
The one thing the evidence rules out is the middle position — phasing in because it feels like the responsible default, without knowing what it costs you. That's the version that gets you the lower return and the anxiety.